rosiglitazone hydrochloride (CAS 302543-62-0)

Rosiglitazone hydrochloride, a member of the thiazolidinedione class of drugs, has been extensively studied in scientific research for its effects on cellular metabolism and gene expression. Its primary mechanism of action involves activation of peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor that regulates gene transcription related to glucose and lipid metabolism. By binding to PPARγ, rosiglitazone hydrochloride promotes adipocyte differentiation, enhances insulin sensitivity, and reduces hepatic glucose output. In research, rosiglitazone hydrochloride has been used to investigate the molecular mechanisms underlying insulin resistance, type 2 diabetes mellitus, and metabolic syndrome. Additionally, its effects on PPARγ activity have been explored in the context of obesity-related complications, cardiovascular diseases, and non-alcoholic fatty liver disease. Moreover, rosiglitazone hydrochloride has been employed as a pharmacological tool to explain the roles of PPARγ in various cellular processes, including inflammation, oxidative stress, and vascular function. Its ability to modulate PPARγ activity makes rosiglitazone hydrochloride a valuable asset in studying metabolic disorders and exploring potential targets for metabolic syndrome and related conditions.